Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?
- PMID: 30613654
- PMCID: PMC6291594
- DOI: 10.21037/atm.2018.10.60
Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?
Conflict of interest statement
Conflicts of Interest: M Rizzo has received grants and/or fees from Amgen, Astra Zeneca, Boehringer-Ingelheim, Eli-Lilly, Meda Pharma, Merck, Novo Nordisk, Roche, Servier. N Papanas has been an advisory board member of TrigoCare International, Abbott, AstraZeneca, Elpen, MSD, Novartis, Novo Nordisk, Sanofi-Aventis and Takeda; has participated in sponsored studies by Eli Lilly, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; received honoraria as a speaker for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elpen, Galenica, MSD, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, Takeda and Vianex; and attended conferences sponsored by TrigoCare International, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Pfizer and Sanofi-Aventis. The other authors have no conflicts of interest to declare.
Comment on
-
Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial.JAMA. 2018 May 1;319(17):1773-1780. doi: 10.1001/jama.2018.4072. JAMA. 2018. PMID: 29715355 Free PMC article. Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources